Lessons from phase III clinical trials on anti-VEGF therapy for cancer

By Rakesh K. Jain, D. Duda, Jeffrey W. Clark, Jay S. Loeffler. Nature Clinical Practice Oncology, 2006

1,099 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/8f2d69a96328506f8f19e823c72424ac8c7d0682

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

Vascular endothelial growth factor (VEGF) signaling in tumor progression. (2007, background): “[286] Jain RK, Duda DG, Clark JW, Loeffler JS.”
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. (2013, background): “Although our work has focused on vascular normalization, we are cognizant of other potential mechanisms of benefit from antiangiogenesis alone or when combined with chemotherapy.(165,166) These include killing both endothelial and cancer cells by antiangiogenics (eg, PlGF/Nrp1 antibodies in medullob”
Angiogenesis in brain tumours (2007, background): “Three different anti-angiogenic agents that target the vascular endothelial growth factor ( VEGF ) pathway have been approved for the treatment of a number of extracranial tumour”
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. (2007, background): “Establishing the optimal timing of antiangiogenic therapies such as AZD2171 in relation to other cytotoxic therapies is a critical challenge (Brown et al., 2004; Grossman and Batara, 2004; Jain et al., 2006; Prados et al., 2006; Reardon et al., 2005; Tremont-Lukats and Gilbert, 2003).”
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer (2010, neutral): “VEGF receptor kinase–selective multitargeted agents in combination with various chemotherapeutic agents are in different stages of clinical development (19, 20).”
ANTIANGIOGENESIS STRATEGIES REVISITED: FROM STARVING TUMORS TO ALLEVIATING HYPOXIA (2014, background): “This hypothesis, although controversial, offered a potential explanation for why bevacizumab can improve the outcome of chemotherapy and, more importantly, offered guidelines to improve such combination therapies (Jain et al., 2006).”
Autocrine VEGF signaling is required for vascular homeostasis. (2007, neutral): “Other pathologies, while not as consistent, include hemorrhage, proteinuria, intestinal perforations, and congestive heart failure (Jain et al., 2006; Kabbinavar et al., 2003).”
A perivascular niche for brain tumor stem cells. (2007, background): “Angiogenic signaling in tumors is often initiated by oncogenic cell signal pathways (Jain et al., 2006).”
Tumor-stroma interactions in pancreatic ductal adenocarcinoma (2007, background): “Hanover, NJ), which inhibits the tyrosine kinase domains of VEGF receptor/PDGF receptor/c-kit (63).”
The multifaceted circulating endothelial cell in cancer: towards marker and target identification (2006, background): “Although the results of recent clinical trials indicate that some anti-angiogenic drugs might prolong the survival of patients, these problems necessitate the development of alternative pharmacodynamic surrogate markers and their validation at the preclinical and clinical leve”
Molecular mechanisms and clinical applications of angiogenesis (2011, background): “Instead, more success has been achieved by targeting the vascular supply in cancer and eye disease”